MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Phase 2 Completed 25 enrolled Surbhi Sidana, MD

NaSingle-groupOpen-labelTreatment

Summary

This study evaluates a new drug MGTA-145 in combination with plerixafor (Mozobil) to mobilize stem cells into the peripheral blood for collection by apheresis. The stem cells will be used for autologous stem cell transplant for treatment of multiple myeloma.

Timeline

Start: 2020-10-05
Primary completion: 2021-07-22
Completion: 2022-06-30

Outcome

Met primary endpoint

paper 88% (n = 22) of patients met the primary endpoint of collecting 2 ×106 CD34+ cells/kg in ≤ two days PMID 39384609 ↗

Publications

Sidana S, Bankova AK, Hosoya H, Kumar SK, Holmes TH, Tamaresis J, Le A, Muffly LS, Maysel-Auslender S, Johnston L, Arai S, Lowsky R, Meyer E, Rezvani A, Weng WK, Frank MJ, Shiraz P, Maecker HT, Lu Y, Miklos DB, Shizuru JA. Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. Blood Cancer J. 2024 Oct 9;14(1):173. doi: 10.1038/s41408-024-01152-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MGTA-145	Protein / enzyme biologic	0.03 mg/kg	Intravenous
Subject	Plerixafor	Small molecule	0.16 mg/kg	Subcutaneous
Subject	Plerixafor	Small molecule	0.24 mg/kg	Subcutaneous